Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2020-06-12

FDA Approved: TIVICAY PD — Original Application (ViiV Healthcare Company)

View source ↗

Summary

FDA approved Tivicay PD (dolutegravir sodium) under an original application for HIV-1 infection, introducing a new product formulation of dolutegravir.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • TIVICAY PD (dolutegravir sodium)

Snippet

ORIG AP for TIVICAY PD (DOLUTEGRAVIR SODIUM)